mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
Version of Record online: 19 NOV 2010
© 2010 John Wiley & Sons A/S
Pigment Cell & Melanoma Research
Volume 24, Issue 1, pages 254–257, February 2011
How to Cite
Pópulo, H., Soares, P., Faustino, A., Rocha, A. S., Silva, P., Azevedo, F. and Lopes, J. M. (2011), mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell & Melanoma Research, 24: 254–257. doi: 10.1111/j.1755-148X.2010.00796.x
- Issue online: 13 JAN 2011
- Version of Record online: 19 NOV 2010
- Accepted manuscript online: 28 OCT 2010 07:55AM EST
Data S1. Methods.
Figure S1. Graphic representation of the expression levels of PI3K/AKT/mTOR and MAPK pathways effectors in cutaneous melanomas and nevi.
Table S1. Clinico-pathological features of cutaneous melanomas.
Table S2. Description of the antibodies used.
|PCMR_796_sm_AppS1.doc||86K||Supporting info item|
|PCMR_796_sm_FigS1.TIF||57K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.